Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.2 million.

  • Ovid Therapeutics' Net Income towards Common Stockholders rose 1319.43% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.3 million, marking a year-over-year decrease of 1178.12%. This contributed to the annual value of -$26.4 million for FY2024, which is 4949.66% up from last year.
  • Latest data reveals that Ovid Therapeutics reported Net Income towards Common Stockholders of -$12.2 million as of Q3 2025, which was up 1319.43% from -$4.7 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Net Income towards Common Stockholders peaked at $176.0 million during Q1 2021, and registered a low of -$26.0 million during Q4 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$12.0 million (2022), whereas its average is -$2.0 million.
  • Per our database at Business Quant, Ovid Therapeutics' Net Income towards Common Stockholders soared by 97871.45% in 2021 and then tumbled by 15497.01% in 2025.
  • Over the past 5 years, Ovid Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$26.0 million in 2021, then skyrocketed by 55.75% to -$11.5 million in 2022, then crashed by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then tumbled by 31.4% to -$12.2 million in 2025.
  • Its last three reported values are -$12.2 million in Q3 2025, -$4.7 million for Q2 2025, and -$10.2 million during Q1 2025.